SVRA
Savara Inc
Halal Rating :
Last Price
$2.94
Last updated:
Market Cap
-
7D Change
5.2%
1 Year Change
-36.33%
Company Overview
Industries
Exchange
Next Earnings Date
Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. Their lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Savara Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.